These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37555516)

  • 21. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
    Pascoal TA; Mathotaarachchi S; Mohades S; Benedet AL; Chung CO; Shin M; Wang S; Beaudry T; Kang MS; Soucy JP; Labbe A; Gauthier S; Rosa-Neto P
    Mol Psychiatry; 2017 Feb; 22(2):306-311. PubMed ID: 27021814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Ossenkoppele R; Pichet Binette A; Groot C; Smith R; Strandberg O; Palmqvist S; Stomrud E; Tideman P; Ohlsson T; Jögi J; Johnson K; Sperling R; Dore V; Masters CL; Rowe C; Visser D; van Berckel BNM; van der Flier WM; Baker S; Jagust WJ; Wiste HJ; Petersen RC; Jack CR; Hansson O
    Nat Med; 2022 Nov; 28(11):2381-2387. PubMed ID: 36357681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of a [
    Coomans EM; de Koning LA; Rikken RM; Verfaillie SCJ; Visser D; den Braber A; Tomassen J; van de Beek M; Collij LE; Lemstra AW; Windhorst AD; Barkhof F; Golla SSV; Visser PJ; Scheltens P; van der Flier WM; Ossenkoppele R; van Berckel BNM; van de Giessen E
    Neurology; 2023 Nov; 101(19):e1850-e1862. PubMed ID: 37748892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
    Yang HS; Yau WW; Carlyle BC; Trombetta BA; Zhang C; Shirzadi Z; Schultz AP; Pruzin JJ; Fitzpatrick CD; Kirn DR; Rabin JS; Buckley RF; Hohman TJ; Rentz DM; Tanzi RE; Johnson KA; Sperling RA; Arnold SE; Chhatwal JP
    Brain; 2024 Jun; 147(6):2158-2168. PubMed ID: 38315899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease.
    Beyer L; Schnabel J; Kazmierczak P; Ewers M; Schönecker S; Prix C; Meyer-Wilmes J; Unterrainer M; Catak C; Pogarell O; Perneczky R; Albert NL; Bartenstein P; Danek A; Buerger K; Levin J; Rominger A; Brendel M
    Neuroimage Clin; 2019; 24():101949. PubMed ID: 31398553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroimaging biomarkers of glial activation for predicting the annual cognitive function decline in patients with Alzheimer's disease.
    Yasuno F; Kimura Y; Ogata A; Ikenuma H; Abe J; Minami H; Nihashi T; Yokoi K; Hattori S; Shimoda N; Watanabe A; Kasuga K; Ikeuchi T; Takeda A; Sakurai T; Ito K; Kato T
    Brain Behav Immun; 2023 Nov; 114():214-220. PubMed ID: 37648003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline.
    Toledo JB; Rashid T; Liu H; Launer L; Shaw LM; Heckbert SR; Weiner M; Seshadri S; Habes M;
    PLoS One; 2022; 17(11):e0276392. PubMed ID: 36327215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perivascular Space Predicts Brain Hypometabolism of Individuals with Underlying Amyloid Pathology.
    Shi X; Zhou N; Sun B; Wu Y; Hu Y; Ning Y;
    J Alzheimers Dis; 2022; 90(3):1329-1337. PubMed ID: 36245373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Cognitive Progression Due to Alzheimer's Disease in Normal Participants Based on Individual Default Mode Network Metabolic Connectivity Strength.
    Zhang Q; Li F; Wei M; Wang M; Wang L; Han Y; Jiang J;
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 Jul; 9(7):660-667. PubMed ID: 38631552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Multi-Dimensional Comparison of Alzheimer's Disease Neurodegenerative Biomarkers.
    Liu Y; Han PR; Hu H; Wang ZT; Guo Y; Ou YN; Cao XP; Tan L; Yu JT;
    J Alzheimers Dis; 2022; 87(1):197-209. PubMed ID: 35275546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
    Groot C; Smith R; Stomrud E; Binette AP; Leuzy A; Wuestefeld A; Wisse LEM; Palmqvist S; Mattsson-Carlgren N; Janelidze S; Strandberg O; Ossenkoppele R; Hansson O
    Brain; 2023 Apr; 146(4):1580-1591. PubMed ID: 36084009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.
    Caprioglio C; Garibotto V; Jessen F; Frölich L; Allali G; Assal F; Frisoni GB; Altomare D;
    J Alzheimers Dis; 2022; 89(2):535-551. PubMed ID: 35912743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
    Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
    J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.